IGPR-1 interacts with MIA to regulate melanoma cell migration and invasion by Amraei, Razie
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
IGPR-1 interacts with MIA to
regulate melanoma cell migration
and invasion
https://hdl.handle.net/2144/34808
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
IGPR-1 INTERACTS WITH MIA TO REGULATE MELANOMA CELL 
 
MIGRATION AND INVASION 
 
 
 
 
by 
 
 
 
 
RAZIE AMRAEI 
 
M.D., Shahid Beheshti University of Medical Sciences, 2013 
 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2019 
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                      ©   2019 by 
                                     RAZIE AMRAEI 
                                       All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Nader Rahimi, Ph.D. 
 Associate Professor 
 Department of Pathology & Laboratory Medicine 
 
 
Second Reader   
 Christopher D. Andry, M.Phil., Ph.D. 
 Associate Professor 
 Department of Pathology & Laboratory Medicine 
 
 
 
		 iv 
 
ACKNOWLEDGMENTS 
 
Firstly, I would like to express my sincere gratitude to Dr. Rahimi for his constant 
encouragement, motivation and patience during this project. His philosophical approach to 
science and dedication to education changed my understanding of science and life. I would 
also like to thank Dr. Andry for all his support during my master and his input on my thesis. 
I thank my lab mates in Dr. Rahimi lab, Rachel, Kevin, Rawan, Ashley and Daniel for their 
friendship, help and positive energy. Finally, my heartfelt thanks goes to my family, my 
parents, my brothers and my sister, whose love and guidance are with me in whatever I 
pursue.  
		 v 
IGPR-1 INTERACTS WITH MIA TO REGULATE MELANOMA CELL  
MIGRATION AND INVASION 
RAZIE AMRAEI 
ABSRACT  
 Melanoma represents one of the most aggressive and deadliest form of skin cancer. 
Melanoma inhibitory activity (MIA) also called cartilage-derived retinoic acid-sensitive 
protein (CD-RAP) is a small secreted protein with a single Src Homology 3 (SH3) domain-
like fold with N- and C-terminal extensions. MIA interacts with extracellular matrix 
proteins (ECM), such as fibronectin, laminin, tenascin, ECM receptors and integrins. It is 
proposed that MIA by interacting with ECM or integrins inhibits cell-ECM adhesion leads 
to increased melanoma cell migration and tumor invasion. However, the experimental data 
to support this proposed function of MIA remains poorly understood.  We have identified 
immunoglobulin-containing and proline-rich receptor-1 (IGPR-1) as a novel binding 
partner for MIA. The main objectives of this project were to investigate IGPR-1 expression 
in human melanoma cell lines and primary tumors and explore the biological importance 
of IGPR-1/MIA axis in melanoma cell function. Our findings revealed that IGPR-1 
expression is downregulated in melanoma cell lines. However, different levels of IGPR-1 
expression have been observed. Moreover, IGPR-1 expression was significantly 
downregulated in human primary melanoma tumors. We demonstrate that co-expression 
of IGPR-1with MIA promotes cell survival and increase cell-cell adhesion. Taken together, 
our data suggests that IGPR-1/MIA pathway could regulate melanoma cell invasion and 
metastasis. We propose a novel cytosolic signaling function for MIA in melanoma cells. 
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INTRODUCTION 
 
Endothelial cells are the main component of the blood circulatory system, which 
delivers oxygen and nutrients to all tissues in vertebrate animals.  In addition, they perform 
a crucial role in hemostasis, immune system, angiogenesis and vascular permeability 
(Félétou & Vanhoutte, 2006).  Endothelial cells are necessary to sustain blood fluidity, 
control of coagulation pathway and regulation of platelet activation (van Hinsbergh, 2012). 
Moreover, endothelial cells can trigger innate and acquired immune responses due to 
activation by cytokines, metabolic stress and hypoxia (Fraisl, Mazzone, Schmidt, & 
Carmeliet, 2009) (Pober & Sessa, 2007). Importantly, integrity of endothelial cells and 
vascular permeability are associated with dynamic function of blood vessels. In fact, 
change in endothelial barrier function is the major component in various biologic 
conditions range from development and physiology to disease and pathophysiology 
(Rahimi, 2017). Considering various tasks of endothelial cells, they evolved into highly 
specialized structures in each organ such as blood brain barrier in central nervous system 
or glomerular capsule in kidney. Furthermore, in each organ multiple forms of intercellular 
junctions are used to maintain cellular integrity and perform specific roles through 
intracellular signaling pathways (Franke, 2009). In other words, based on the type of tissue 
and prerequisite cellular functions, junctional structures comprise adherent junctions, tight 
junctions, gap junctions and desmosomes (Bazzoni & Dejana, 2004). Furthermore, both 
physical and biochemical communication of cells at these junctions are mediated by a 
diverse group of cell surface receptors such as junctional adhesion molecules (JAMS), 
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claudins family proteins, occludin, vascular endothelial-cadherin and newly characterized 
immunoglobulin-containing and proline-rich receptor-1(IGPR-1) (Rahimi, 2017). 
Adherence  junctions (AJs) are one of the major cell-cell junctions in endothelial cells and 
in addition to control the vascular permeability by active opening and closure of the 
junction, they are essentially required for preservation of existing vessels, formation of new 
vessels, and transmigration of circulatory leukocytes (Lampugnani, Dejana, & Giampietro, 
2017). Adherent junctions are mainly composed of vascular endothelial cadherin (Dejana, 
Orsenigo, & Lampugnani, 2008). Moreover, as VE-cadherin and other adhesive proteins 
at AJs are connected to intracellular signaling and cytoskeletal partners, adherent junctions 
have a significant impact on signaling and transcriptional pathways and cell polarity 
(Wheelock & Johnson, 2003)(Lampugnani et al., 2002).  
Tight junctions, as a continuous intercellular barrier, control permselectivity (based on size, 
electrical resistance and ionic charge) in monolayer structures in endothelial and epithelial 
tissue (Anderson & Van Itallie, 2009). Several studies have suggested that compared to 
adherent junctions, tight junctions are formed in later stages of intercellular communication 
(Bazzoni & Dejana, 2004). In addition, more than 40 proteins have been discovered which 
are specially localized to tight junctions (Schneeberger & Lynch, 2004)(Yamazaki, Okawa, 
Yano, Tsukita, & Tsukita, 2008). However, claudins family proteins are the key factors in 
the structure and function of tight junctions (Furuse, 2009). Also, occludin is another type 
of four transmembrane domain-containing which is incorporated in tight junctions 
(Ikenouchi et al., 2005).  
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Gap junctions make an intercellular channel which is a double-membrane, firmly sealed 
space between neighboring cells (Segretain & Falk, 2004). These hydrophilic channels also 
allow direct transport of signaling proteins, ions and small molecules between adjacent 
cells (Beyer & Berthoud, 2017). Although it has been presumed that gap junctions are made 
simpler than other junctional structures but recent studies using GST-pull-down assay and 
proteomic analysis have shown a large number of binding proteins to gap junctions (Singh 
& Lampe, 2003) (Peebles, Duncan, Ruch, & Malkinson, 2003). Desmosomes, as another 
group of junctional structures, are functional in calcium-dependent manner. They  are 
linked to intermediate filament cytoskeleton and connect cells through the extracellular 
domains (Kowalczyk & Green, 2013) . In fact, based on type of the tissue (such as 
gastrointestinal system, urinary tract and skin) and mechanical stress level, several 
isoforms of desmosomal complexes have been observed in epithelial cells (Getsios, Huen, 
& Green, 2004) (Holthöfer, Windoffer, Troyanovsky, & Leube, 2007).  
Notably, desmosomes are not present in endothelial cells (Pieperhoff, Barth, Rickelt, & 
Franke, 2010). However, desmosomal-like structures in endothelial cells of lymphatic 
veins have been described (Schmelz, Moll, Kuhn, & Franke, 1994).Three superfamily of 
proteins are involved in desmosomes: Cadherins, Armadillo proteins and plakins (Patel & 
Green, 2014). Regarding the significance of desmosomes, loss of Epithelial-cadherin (E-
cadherin) is an important maker in diagnosis and prognosis of multiple epithelial cancers 
(Van Roy, 2014).  
Although endothelial integrity and barrier function are supported by above mentioned 
junctional structures and many other complexes, there are various molecules and proteins 
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to disrupt the endothelial barrier continuity and increase the vascular permeability 
including: histamine, bradykinin, fibrinogen, tumor necrosis factor-a (TNF-a), 
interleukin-8 (IL-8), etc. (Rahimi, 2017). In addition, vascular endothelial growth factor 
(VGEF) which promotes angiogenesis, can also destabilize endothelial barrier in various 
conditions such as cancer, ischemic disease (Weis & Cheresh, 2005), diabetic retinopathy 
and inflammation (Caldwell et al., 2003) (Pober & Sessa, 2007).  Precisely, VEGF 
receptor-2 (VEGFR-2) is mainly involved in regulation of vascular permeability (Suarez 
& Ballmer-Hofer, 2001). VEGF induces multiple posttranslational modifications like 
methylation and phosphorylation on VEGFR-2, which stimulates various signaling 
pathways. Recruitment of the signaling proteins to VEGFR-2 regulates endothelial cells 
junction, migration and proliferation (Rahimi & Costello, 2015). Moreover, VEGFR-2 
mediates vascular permeability through direct effects on endothelial junctional proteins 
such as integrins and VE-cadherin (Weis & Cheresh, 2005). Multiple pathways have been 
identified to disrupt endothelial barrier continuity and increase vascular permeability. 
Therefore, achieving the proper balance between these two contour-regulatory mechanisms 
is a fundamental principle in healthy endothelial cells, which needs active coworkers. In 
fact, cell adhesion molecules at cell-cell junctions regulate endothelial cells integrity and 
vascular permeability. 
 
Cell Adhesion Molecules (CAMs): Regulators of Endothelial Cells Functions and 
Communications 
A mixed group of transmembrane proteins provides physical junctions in endothelial cells. 
Additionally, they are involved in intracellular signaling pathways in association with 
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multiple cytoplasmic proteins (Franke, 2009). CAMs can also act as a receptor for 
pathogenic organisms like viruses. Junctional adhesion molecules (JAMs), a large family 
of CAMs, have been characterized in Coxsackie and adeno virus receptor (CAR). 
Moreover, hepatitis C virus , which is the most common cause of chronic liver disease in 
the united states and world (Kish, Aziz, & Sorio, 2017), employs claudins and occludin for 
access to hepatocytes (Mateo, Generous, Sinn, & Cattaneo, 2015). Interestingly, adhesion 
molecules can significantly influence the outcome of therapeutic interventions such as 
surgical procedures, immunosuppressive treatments and chemotherapy (Lee et al., 2017). 
For instance, targeting IGPR-1, a recently found cell adhesion molecule, leads to increased 
tumor cell sensitivity to chemotherapeutic agents in colon cancer (Woolf et al., 2017).  
 
Vascular Endothelial Cadherin 
Vascular endothelial-cadherin (VE-cadherin also called cadherin-5) is considered a main 
integral membrane protein at adherence junctions (Dejana, Tournier-Lasserve, & 
Weinstein, 2009). VE-cadherin is a member of cadherin family of cell adhesion molecules 
and expressed by endothelial cells as a cell-type specific transmembrane adhesion protein 
(Dejana, 2004). Cytoplasmic C-terminal of VE-cadherin is the binding site for b-catenin, 
p-120 catenin, plakoglobin and armadillo family of proteins (Dejana & Vestweber, 2013). 
In embryonic development, VE-cadherin is essential for stable vascular system formation. 
However, in adult life, it regulates vascular permeability and restricts uncontrolled vascular 
growth (Giannotta, Trani, & Dejana, 2013). Interestingly, multiple studies have suggested 
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the regulatory role of VEGF on VE-cadherin function through phosphorylation at tyrosine 
residues (Wallez et al., 2007) (Eliceiri et al., 1999). 
 
Claudins 
Claudins are the main component of tight junctions which mediate cell-cell adhesion in 
epithelial and endothelial cells (Furuse, 2009). Claudins, a family of 24 transmembrane 
proteins, have two extracellular loops in their general structure as they pass the bilayer cell 
membrane four times and their N- and C- termini are located into cytoplasm (Findley & 
Koval, 2009). Since PZD-binding domain is present at C-terminal of all claudins (Except 
claudin-12), they are able to directly interact with PDZ-containing cytoplasmic proteins 
such as Zonula Occludens-1, -2, -3 (ZO1, 2 and 3) and multi-PDZ domain protein-1 
(MUPP)-1 (Krause, Protze, & Piontek, 2015).  Several roles of claudins have been reported 
in both physiological and pathological processes. Particularly, binding to ZO-1 and ZO-2 
scaffolding proteins connects claudins to actin cytoskeleton which is required for tight 
junction assembly and function (Umeda et al., 2006).  In addition, changes in claudins 
expression are associated with epithelial-mesenchymal transition (EMT), a transformation 
process of polarized epithelial cells to fibroblastic mesenchymal cells. Importantly, EMT 
occurs in embryonic development, physiologic response to epithelial stress and 
carcinogenesis (Ikenouchi, Matsuda, Furuse, & Tsukita, 2003). Furthermore, pivotal 
functions of different claudins isoforms in tissue and vascular permeability have been 
demonstrated in human and mice diseases (Findley & Koval, 2009). For instance, lethal 
neonatal phenotype due to skin permeability disorders, has been observed in claudin-1 null 
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mice. Additionally in humans, hearing loss and recessive renal hypomagnesaemia have 
been reported as a result of claudin-14 and claudin-16 mutations, respectively (Wattenhofer 
et al., 2005)(Weber et al., 2001). In fact, these mutations disrupt lymphatic and endothelial 
barrier and change paracellular vascular permeability to electrolytes. In addition to 
mutations, various protein and lipid posttranslational modifications such as 
phosphorylation and palmitoylation can affect claudins activity (Van Itallie, Gambling, 
Carson, & Anderson, 2005). Studies have shown that palmitoylated claudins are more 
efficient in tight junction structure formation (Nusrat et al., 2000). Interestingly, regulation 
of claudins function by phosphorylation is more complex and can increase or decrease 
claudins activity in different pathways (Findley & Koval, 2009). 
 
Occludin 
Occludin is another four-transmembrane protein localized at tight junctions in epithelial 
and endothelial cells (Feldman, Mullin, & Ryan, 2005). It is a 65kDa protein with 
approximately 90% homology in amino acid sequence between mammalians (Ando-
Akatsuka et al., 1996). Studies have shown that C-terminus of occludin is necessary for 
interaction with adaptor proteins like ZO-1, multiple other signaling functions and occludin 
dimerization (Cummins, 2012) (Walter et al., 2009). Occludin key function in 
transepi/endothelial electrical resistance has been confirmed in multiple investigations 
(McCarthy et al., 1996)(Hirase et al., 1997) . Surprisingly, loss of occludin in mouse does 
not alter tight junctions. However, under chronic inflammation decreased in tight junction 
stability was observed  (Saitou et al., 2000). Several similar results from other experiments 
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suggest that occludin is involved in tight junctions integrity (instead of assembly) and 
advanced barrier functions (Cummins, 2012). Indeed, occludin altered function has been 
demonstrated in many diseases like diabetes and inflammatory bowel disease (Harhaj et 
al., 2006) (Edelblum & Turner, 2009).  Similar to claudins, occludin is subjected to variety 
of posttranslational modifications. In a study on retinal endothelial cells, VEGF activation 
increased occludin phosphorylation and vascular permeability (Harhaj et al., 2006). 
Furthermore, there are data suggest that serine/threonine and tyrosine phosphorylation sites 
at C-terminus of occludin regulate recruitment of PDZ- and SH3 containing proteins (Kale, 
Naren, Sheth, & Rao, 2003) (Tash et al., 2012). 
 
Immunoglobulin-containing and proline-rich receptor-1:   
 
Immunoglobulin-containing and proline-rich receptor-1 (IGPR-1), a previously 
uncharacterized protein, was identified as a novel member in Ig-containing family of cell 
adhesion molecules (Rahimi, Rezazadeh, Mahoney, Hartsough, & Meyer, 2012). Ig-
containing adhesion molecules are involved in regulation of cell-cell adhesion and cell 
migration in normal development and pathological conditions like inflammation and 
cancer (Takai, Miyoshi, Ikeda, & Ogita, 2008)(DeLisser et al., 2010).  Furthermore, Ig-
containing adhesion molecules play a role in specificity of cell-cell recognition while their 
Ig domain participate in protein-protein and protein-ligand interactions (Barclay, 
2003)(Rahimi, 2006). IGPR-1 is expressed in various cell types including epithelial and 
endothelial cells (Rahimi et al., 2012). IGPR-1 is a glycoprotein which contains one Ig 
domain, single transmembrane domain and a cytoplasmic region rich in proline residues 
(Rahimi et al., 2012). Interestingly, IGPR-1 gene has been found in advanced eukaryotes 
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including primates, bovine, dolphins, canines, horses, etc. whereas, it is not present in rat 
or mouse genome (Rahimi et al., 2012). However, transmembrane and immunoglobulin-
containing 1 (TMIGD1), an adhesion molecule which is closely related to IGPR-1, is 
expressed  in both human and mice renal epithelial cells (Arafa et al., 2015). In other words, 
absence of IGPR-1 in rodents highlights profound differences between this unique 
molecule and classical cell adhesion molecules which are present in different species. 
Considering the interspecies evolution of cell adhesion molecules, probably this distinct 
receptor evolved to perform specific functions in higher mammalians.  
IGPR-1 is expressed in endothelial and epithelial cells predominantly and it is present in  
multiple human organs including skin, colon, bone marrow, lung and liver (Rahimi et al., 
2012). IGPR-1 is localized at cell membrane in a di-sulfide linked cis-dimer structure. 
Then, trans-homophilic dimerization with neighboring cells triggers phosphorylation of 
serine 220 at cytoplasmic region which is essential for IGPR-1 activation (Wang et al., 
2016). Importantly, IGPR-1 is highly glycosylated at its extracellular region and additional 
analysis showed that using glycosylation inhibitors caused IGPR-1 degradation.    In 
addition, it was demonstrated that IGPR-1 is localized at adherence junctions in endothelial 
cells. In fact, it regulates cell-cell adhesion and cell migration and it is required for 
angiogenesis (Rahimi et al., 2012). Further studies have shown that IGPR-1 plays a major 
role in vascular permeability and endothelial barrier function. To be more precise, IGPR-1 
expression in porcine aortic cells (PAE) significantly increased trans-endothelial electrical 
resistance (TEER). Moreover, using fluorescently labeled dextran, confirmed that IGPR-1 
expression decreased vascular permeability in PAE cells (Wang et al., 2016). These 
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experiments propose a probable role of IGPR-1 in conditions related to disrupted 
endothelial barrier function such as diabetes, inflammation and cancer. 
 
 
 
              Figure1. Mechanism of IGPR-1 activation and function. (Wang et al., 2016) 
 
 
However, IGPR-1 potential role in cancer is not limited to regulation of endothelial cell 
function. For instance, it was found that IGPR-1 expression is upregulated in human 
primary colon cancer and it promotes colon cancer tumor cell growth in mouse tumor 
xenograft model. Additionally, IGPR-1 adhesive functions support tumor multicellular 
aggregation which increases colorectal tumors resistance to chemotherapeutic drugs 
(Woolf et al., 2017). Similarly, recent study indicated that IGPR-1 could bind to a new 
member of B7 family proteins which are known for T-cell regulation (Janakiram, Chinai, 
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Zhao, Sparano, & Zang, 2015). HHLA2 (HERV-H LTR-associating 2) is a newly 
identified B7 protein which is expressed in a few organs in physiologic condition such as 
placenta, kidney and breast. Conversely, HHLA2 is highly expressed in multiple human 
cancers including colon, kidney, lung, breast, skin, etc. (Janakiram et al., 2014). Although 
molecular mechanisms of IGPR-1 binding to HHLA2 are not fully understood, their 
interaction introduced a potential immunotherapeutic target in cancer management.  
Another important aspect of IGPR-1 function and structure is a proline rich sequence at C-
terminal cytoplasmic domain. Indeed, proline rich sequences are recognized for interaction 
with SH3 containing signaling proteins and regulation of protein-protein bindings (Cuadrat 
et al., 2014). Correspondingly, IGPR-1 associates with multiple SH3 containing signaling 
proteins through its cytoplasmic proline rich motif including SPIN90/WISH (SH3 Protein 
Interacting with Nck90), calcium channel b2 subunit (CACNB2), bullous pemphigoid 
antigen-1 (BPAG1) and melanoma inhibitory activity (MIA) (Rahimi et al., 2012).   
SPIN90, SH3 protein interacting with Nck90 (also known as WISH and DIP), is involved 
in angiogenesis, actin polymerization, cell morphology and cell adhesion (Rahimi, 2017). 
In fact, inhibition of capillary tube formation after SPIN90 downregulation, confirmed the 
critical role of SPIN90 in angiogenesis. Furthermore, as a SH3 containing protein, it binds 
to N-WASP (Neural- Wiskott–Aldrich syndrome protein), induces Arp2/3 complex 
activation and promotes actin polymerization (Takenawa & Suetsugu, 2007). 
Additionally, research has shown that SPIN90, as an adaptor protein, recruits proteins 
like WASP to Nck90 and regulates cell-cell adhesion (Lim et al., 2003). Considering the 
biological importance of SPIN90 in both normal angiogenesis and pathological 
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conditions, for instance a life-threatening disease such as Wiskott–Aldrich syndrome, 
IGPR-1 binding to SPIN90 reflects significant signaling potentials of this newly 
identified receptor.  
CACNB2, as an oligomeric protein , is a subunit of L-type voltage-pendent calcium 
channels which mediate calcium entry into cells (Yamagata & Sanes, 2008). In fact, 
CACNB2 performs a significant role in regulation of calcium channel activity (M Soldatov, 
2015). Recent studies have provided strong evidence about CACNB2 role in three 
categories of cardiovascular disease: hypertension, heart failure and arrhythmia. In other 
Words, several genome-wide association studies (GWAS) confirmed CACNB2 
association with hypertension (HO et al., 2011) (Levy et al., 2009). Moreover, CACNB2 
expression is upregulated in failing human hearts (Hullin et al., 2007). Additionally, 
genetic mutations in CACNB2 have been observed in some forms of lethal arrhythmia like 
Brugada syndrome (Antzelevitch et al., 2007). Therefore, in the last few years CACNB2 
has emerged as a novel pharmacological target in cardiovascular disease.  On the other 
hand, in a mechanistic study about endothelial cell response to flow shear stress (submitted 
2018), it was confirmed that IGPR-1 acts as a mechanosensor receptor in endothelial cells 
and plays a major role in mechanotransduction signaling in endothelial remodeling. 
Precisely, flow shear stress caused IGPR-1 activation. Furthermore, nanomechanical 
characterization of PAE cells via atomic force microscopy (AFM) revealed that IGPR-1 
expressing cells were considerably stiffer compared to control group.  Taken together, 
IGPR-1 interaction with CACNB2, a protein which is highly associated with hypertension, 
and IGPR-1 remarkable ability to convert mechanical forces into cellular responses, 
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provide a new insight into IGPR-1 mechanosensory characteristics and possible therapeutic 
implications of this receptor in cardiovascular disease.  
BPAG1, bullous pemphigoid antigen-1, is a SH3-containg protein from spectraplakins 
family which are cytoskeletal linker proteins. They connect cytoskeletal filaments to each 
other and cell junctions (Leung et al., 2002)(Jefferson, Leung, & Liem, 2004). Therefore, 
BPAG1 contains a actin-binding domain at N-terminus and intermediate filament-binding 
domain at C-terminus (Rahimi, 2017). There are multiple BPAG1 isoforms and it 
expressed in various organs such as brain, skin, heart, etc. (Ali et al., 2017). In fact, genetic 
mutations of BPAG-1 are culprits of a devastating neurological disease called hereditary 
sensory autonomic neuropathy type VI (HSAN-VI) and a skin-blistering disease called 
epidermolysis bullosa (EB) (Künzli, Favre, Chofflon, & Borradori, 2016). Interestingly 
enough, angiogenesis is typically decreased in chronic ulcers but in EB chronic wounds  
increased angiogenesis and vascular permeability have been observed (Cianfarani, 
Zambruno, Castiglia, & Odorisio, 2017). Another supporting evidence for possible role of 
BPAG1 in endothelial cells is that several gene array analyzes confirmed BPAG1 
expression in human endothelial cells of lung, umbilical cord artery and vein as well as 
mouse retinal endothelial cells (Fukushima et al., 2011)(Cheranova, Gibson, Kibiryeva, 
Zhang, & Shui, 2012) (Aranguren et al., 2013).  
Melanoma inhibitory protein (MIA) is another SH3 containing protein that interacts with 
IGPR-1(Rahimi et al., 2012). It is synthesized by malignant melanoma cells and secreted 
to extracellular compartment (Lougheed, Holton, Alber, Bazan, & Handel, 2001). MIA 
was reported to promote melanoma metastasis formation by increased detachment of 
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malignant melanocytes from extracellular matrix components (Sandru et al., 2014). In fact, 
studies demonstrate that MIA interacts with extracellular matrix components such as 
integrin and fibronectin (Lougheed et al., 2001).  
 
 
 
 
Figure 2. Cytoplasmic SH3-containing signaling proteins interacting with IGPR-1 
 
 
 
Melanoma  
Over the last three decades, melanoma incidence rate has increased faster than any other 
cancer types in the Caucasian population in the world (Giblin & Thomas, 2007). Higher 
incidence rate may reflect increased level of awareness and early detection programs. 
However, constantly rising mortality rate of melanoma has challenged the efficacy of 
targeted health polices and medical practice guidelines over the same period (Karagiannis, 
Fittall, & Karagiannis, 2015). Notably, although melanoma constitutes less than 5 percent 
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of all dermatologic malignancies, it causes 80 percent of deaths due to skin cancer (Miller 
& Mihm Jr, 2006). Multiple benign or atypical nevi, a family history of melanoma and 
exposure to ultraviolet radiation are known as melanoma risk factors (Miller & Mihm Jr, 
2006), although multiple etiologic features of melanoma are poorly understood (Gandini 
et al., 2005). 
Similar to other melanocytic neoplasms, cutaneous melanoma (also known as malignant 
melanoma) originates from melanocytes. These cells are mainly located in basilar 
epidermis in skin  and their key function is melanin production (Shain & Bastian, 2016). 
As a defensive measure to ultraviolet radiation, melanocytes synthesize melanin and 
transfer it to their adjacent keratinocytes because melanin is able to absorb energy and 
prevent UV-induced DNA damage in keratinocytes (Miller & Mihm Jr, 2006). Different 
lines of evidence provide association between melanoma development and ultraviolet 
radiation dose, pattern, duration, etc. (Gandini et al., 2005)(Miller & Mihm Jr, 2006).   
At the cellular level, melanocytes do not divide frequently (less than twice per year) and 
(Shain & Bastian, 2016) even in benign nevi , as a first precursor of melanoma, 
melanocytes proliferation is disrupted by senescence (Miller & Mihm Jr, 2006). Therefore, 
the risk of transformation of any individual nevus to melanoma is rare (Clark et al., 
1984)(Goldstein & Tucker, 2013). However, oncogenic pathways can stimulate 
melanocytes proliferation. For instance, activation of the mitogen-activated protein kinase 
(MAPK) signaling pathway (also known as extracellular-related kinase [ERK]) promotes 
melanocytes proliferation. In fact, MAPK activation is caused by somatic mutations of 
BRAF and N-RAS which are associated with 50 and 15 percent of melanoma cases, 
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respectively(Brunet et al., 1999) (Welsh et al., 2001). Surprisingly, BRAF mutation 
frequencies in benign nevi, primary and metastatic melanoma are similar (Pollock et al., 
2003). This data suggests that perhaps melanocytes with dysregulated proliferation in nevi, 
need additional changes to develop malignant melanoma and animal experiments have 
supported this hypothesis. In zebra fish, BRAF mutation caused proliferation of 
melanocytes similar to human nevi. Whereas, BRAF mutation combined with inactivation 
of the tumor-suppressor gene p53 led to malignant melanoma (Patton et al., 2005). 
Furthermore, inactivation of CDKN2A gene which encodes two tumor-suppressor proteins 
(p16 and p19) have been observed in  25 to 40 percent of familial melanoma (Thompson, 
Scolyer, & Kefford, 2005) and inactivation of PTEN , another tumor suppressor,  is present 
in 25 to 50 percent of non-familial melanoma cases (Wu, Goel, & Haluska, 2003). 
However, in murine models of melanoma CDKN2A or PTEN alone did not produce 
melanoma (You et al., 2002). In fact, different results of the same mutation suggest that 
these mutations are steps to melanoma progression and development but there are other 
factors in melanocytes microenvironment that can influence the course of disease. 
In addition to unknown etiologic features of primary melanoma, metastasis formation has 
been a major challenge in melanoma treatment because it affects prognosis significantly. 
For instance,  5-year survival for localized melanoma is around 95 percent in comparison 
to 15 percent for metastatic melanoma (American Cancer Society, 2017). In fact, local 
invasion and vertical growth of tumor represent invasive and metastatic characteristics of 
the melanoma and its actual measurement is used in staging and prognosis evaluation. 
Importantly, local invasion and metastasis formation of melanoma is associated with 
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changes in cell-cell adhesion (Miller & Mihm Jr, 2006). Cadherins are one of the cell 
adhesion molecules, which are involved in melanoma cells dissociation and invasion. 
Precisely, wingless-type mammary tumor virus integration-site family (WNT) pathway 
activation, allows b-catenin disconnection from cadherin. Then, translocated b-catenin 
changes expression of the group of genes which promote melanoma cell survival and 
proliferation (Miller & Mihm Jr, 2006). In fact, loss of expression of E-cadherin is a marker 
of vertical growth and melanoma cells invasion (E. H. Danen, Morandini, Ghanem, & 
Ruiter, 1996).  
Integrins are another family of cell adhesion molecules that their role in melanoma invasion 
and metastasis formation have been studied. They regulate cell adhesion to extracellular 
matrix components such as fibronectin, collagen and laminin (Barczyk, Carracedo, & 
Gullberg, 2010). Research has shown that progression from radial to vertical growth of 
melanoma is associated with aVb integrin expression (E. H. J. Danen et al., 1994). 
Moreover, multiple studies confirmed that melanoma inhibitory protein (MIA) binds to 
fibronectins and prevents them from interaction with integrin. Therefore, it promotes 
melanoma cells detachment from extracellular matrix and increases metastasis potential 
(A.-K. Bosserhoff, 2005). Interestingly, a recent study discovered IGPR-1, as a potential 
protein involved in melanoma by interacting with MIA (Rahimi et al., 2012). MIA is 
proposed to be a secretory protein, however, it is possible that MIA could also play a role 
in signal transduction of IGPR-1 by interacting with IGPR-1.   
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Melanoma inhibitory protein 
Melanoma inhibitory activity protein (MIA) was originally identified from supernatant of 
malignant melanoma cells (Sandru et al., 2014). As it names applies, MIA decreases  
melanocytes proliferation by inhibition of their adherence to cell culture plate (A.-K. 
Bosserhoff, 2005). MIA is a small soluble protein secreted from malignant cells protein 
with apparent molecular weight of 12kDa.  It is not expressed in normal melanocytes 
although it was found in normal chondrocytes which was originally called cartilage-derived 
retinoic acid-sensitive protein (CD-RAP)(Lougheed et al., 2001).  
The function of MIA in melanoma is not fully understood as both positive and negative 
roles for MIA were reported in human melanoma. For example, Bosserhoff et al. reported 
a positive  correlation between MIA serum levels and metastasis in melanoma patients (A. 
K. Bosserhoff et al., 1999). Furthermore, expression of MIA has been reported in a large 
number of cancers including, breast cancer, colorectal cancer, glioma and pancreatic 
cancers (Aung et al., 2006). 
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                Figure 3. MIA interaction with integrins and fibronectin in extracellular    
                               space in melanoma cells 
 
A recent study on pancreatic cancer discovered that MIA mRNA is 42-fold higher 
compared to normal pancreas tissue. Yet, MIA serum levels were unchanged in patients 
and healthy donors (El Fitori et al., 2005). Surprisingly, in this study MIA expression was 
detected in muscular layer of vessels in normal pancreas tissue.  
MIA family proteins include MIA, Otoraplin (OTOR, also called MIA like) , MIA2 and 
Transport and Golgi organization protein 1 homolog (TGO1, also called MIA3) (Riechers 
& Bosserhoff, 2014). Their  shared characteristics include 34%-45% identity in amino acid 
sequence, 47%-59% cDNA sequence homology, a highly conserved SH3 domain  (Figure 
4) and a secretary signal sequence at hydrophobic N-terminal (Sasahira et al., 2016).  
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Figure 4. Amino acid sequence alignment of MIA family proteins. (A) Amino acid 
sequence alignment of MIA, MIA2, MIA3/TGO1 and OTOR are shown (complete amino 
acid sequences of MIA3/TGO1 and MIA2 are not shown). The boxed amino acid 
sequences indicate the Src homology 3 (SH3) domain. (B) Schematic of MIA family 
proteins is shown.  (C) MIA family proteins tree is shown. 
 
OTOR gene is also known as Fibrocyte-derived protein (FDP) which was discovered from 
human fetal cochlear cDNA library (Cohen-Salmon et al., 2000) (Rendtorff et al.,2001) 
and encodes a small extracellular protein similar to MIA. OTOR expression is thought to 
be restricted to inner ear, eye and cartilage (A. K. Bosserhoff & Buettner, 2002). Research 
has shown that during embryonic differentiation of inner ear, alteration of OTOR 
expression plays a key role in chondrogenesis of otic capsule (Cohen-Salmon et al., 2000). 
In addition, a common polymorphism in translation initiation codon and presence of an 
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inactive allele in OTOR gene imply its probable role in inner ear dysfunction (Rendtorff et 
al., 2001).  
MIA2 follows the tissue-specific pattern of expression and it is exclusively expressed in 
liver. Precisely, hepatocyte nuclear factor (HNF) 1 controls MIA2 expression with binding 
sites in the MIA2 promoter (Hellerbrand et al., 2008). In addition, binding sites for SMAD 
and STAT3 were found in MIA2 promoter and treatment with interleukin-6 and TGF-b 
increased MIA2 expression. Importantly, MIA2 mRNA levels correlated with 
inflammation and fibrosis in chronic hepatitis C infection (Anja K. Bosserhoff, Moser, 
Schölmerich, Buettner, & Hellerbrand, 2003). This data suggests that MIA2 can be an acute 
phase protein which represents hepatic disease severity.  Furthermore, MIA2 acts as a 
tumor suppressor gene in hepatocellular carcinoma (HCC) in vitro and in vivo. In fact, 
MIA2 expression is downregulated in HCC and re-expression of MIA2 decreased 
hepatocytes proliferation and invasive potentials (Hellerbrand et al., 2008). On the other 
hand, in a subtype of pancreatic adenocarcinoma, a common genetic variation of MIA2 
increased sensitivity to chemotherapeutic agents and wild-type MIA2 is associated with 
poor prognosis (Kong et al., 2015).  
Transport and Golgi organization protein 1 (TGO1), also known as MIA3, unlike other 
MIA family proteins, is highly expressed in most of the tissues during embryonic 
development and adult life except hematopoietic cells  (A. K. Bosserhoff, Moser, & 
Buettner, 2004). TGO1 Plays a role in the transport of cargos that are too large to fit into 
COPII-coated vesicles (Raote et al., 2017). In addition, TGO1 expression is regulated by 
adhesion of monocytes to substrate.  . TGO1 could regulate cell adhesion, in part through 
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regulation of integrin CD11c activity (Arndt et al., 2007). Moreover, downregulation and 
tumor suppressor activity of TGO1 have been reported in HCC, colon cancer and 
melanoma (Arndt & Bosserhoff, 2007) (Arndt & Bosserhoff, 2006).  
Overall, MIA family proteins exhibit a strong association with malignancies, although their 
detailed roles remain poorly understood. Among all similarities in structure and function, 
an unique feature of these proteins is that they are the first described secretory proteins 
which adopt SH3 domain (Stoll & Bosserhoff, 2008). SH3 domains were originally 
identified as a conserved sequence in Src family tyrosine kinase (Kaneko, Li, & Li, 2008).  
Further studies showed that human genome encodes more than 300 such domains in many 
signaling proteins (Kärkkäinen et al., 2006). They are involved in various cellular processes 
including intracellular signaling, cell-environment communication, cytoskeletal 
rearrangements, cell movement, cell growth, protein trafficking, immune responses 
(Mayer, 2001) (Li, 2005). Most of SH3 domain proteins described to date, bind to proline-
rich sequence containing proteins (Mayer, 2001). 
As mentioned earlier, IGPR-1 through SH3 domain can interact with MIA. The primary 
goal of this thesis project is to investigate IGPR-1 expression and possible effects of IGPR-
1/MIA interaction in human melanoma. 
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SPECIFIC AIMS AND OBJECTIVES 
IGPR-1 is highly expressed in human colon cancer and its over-expression in in human 
colon cancer cell lines stimulates tumor growth (Woolf et al., 2017). However, the potential 
role of IGPR-1 in human melanoma is not known. The primary goals of this project are to 
determine the expression of IGPR-1 in human primary melanoma, specifically whether 
expression of IGPR-1 is altered in melanoma versus normal melanocytes and to investigate 
the functional importance of MIA in IGPR-1 signaling in melanoma. The overall 
hypothesis of this project is that IGPR-1 is downregulated in human melanoma and its 
downregulation results in the aberrant function of MIA. The following specific aims are 
developed to test our hypothesis.   
Specific Aims:     
Specific Aim I: Determine the expression of IGPR-1in human melanoma tumors versus 
normal melanocyte. 
Specific Aim II: Construct retroviral MIA expression system and cell lines.  
Specific Aim III:  Determine the functional role of IGPR-1 and MIA axis in melanoma 
tumor. 
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METHODS  
 
Antibodies and Reagents 
Rabbit monoclonal antibody against Melanoma Inhibitory Activity protein was purchased 
from Invitrogen (Carlsbad, CA). It was used in 1:500 dilutions to detect the presence of 
MIA in HEK-293 cells.  
 
Cell Culture 
Human Embryonic Kidney cells (HEK-293) were grown and maintained in Dulbecco’s 
Modified Eagle’s Media (DMEM) containing 10% fetal bovine serum (FBS) and 50 
units/mL Penicillin and Streptomycin. Cells were placed in a humidified incubator at 37°C 
and 5% CO2. Cells were sub-cultured by using trypsin/EDTA regularly and they were free 
of contamination. For cell culture in suspension experiments cells were plated in non-
adherent culture plates. 
 
Plasmids and constructs 
The cDNA of human melanoma inhibitory activity which was purchased from Invitrogen 
(Carlsbad, CA), was PCR amplified and cloned into retroviral vector pLNCX2 via HindIII 
and NOTI. Similarly, cDNA corresponding Emerald (enhanced version of GFP) was 
purchased from Invitrogen (Carlsbad, CA), was PCR amplified and cloned into retroviral 
vector pLNCX2 via HindIII and SalI  restriction sites. For generation of full length MIA 
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with Emerald, an appropriate HindIII  linker attached to Emerald was ligated to pLNCX2-
MIA.  
 
Cell Transfection 
HEK-293 cells were grown in DMEM 10% FBS media to 60% confluency. Prior to 
transfection, media was removed and 2 mL of serum free DMEM was added to each 60 
mm cell culture dish. Then, DNA-PEI (polyethylenimine) mixtures were prepared in tissue 
culture hood containing 400µl of serum free DMEM, 9µg of (PEI) and 3µg DNA from 
pLNCX2-MIA, pLNCX2-Emerald and pLNCX2-MIA-Emeral plasmids. Following 
incubation for 15 minutes, mixtures were applied onto cells and plates were returned to 
37°C incubator. After 6 hours, 2mL of DMEM 10% FBS were added to plates and the next 
day, existing media (2 mL of serum free DMEM plus 2mL of DMEM 10% FBS) was 
replaced with DMEM 10% FBS gently. 
 
Retroviral Virus production 
 In order to perform retroviral virus production, 293 GPG cells were maintained to 90% 
confluence in GPG Growth Media. Then cells were transfected with pLNCX2-MIA, 
pLNCX2-Emerald, pLNCX2-MIA-Emerald, pLNCX2-MIA/IGPR-1 and pLNCX2-MIA-
Emerald/IGPR-1. After 24 hours, media was replaced with viral producing media and at 
72, 96, 120, and 144 hours the virus was collected as described (Rahimi, et al., 2000, JBC). 
Next, 4ml of virus and 2µl of polybrene were added to HEK-293 cells at 70% confluence 
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on a 60mm plate. DMEM 10% FBS with G418 was added the following day to select for 
transduced cells. 
 
Western Blot Analysis 
 
HEK-293 cells culture dishes were placed on ice, rinsed twice with chilled H/S buffer [20 
mM Hepes (pH 7.4) and 150 mM NaCl] then lysed using lysis (EB) buffer [10mM Tris- 
HCl (pH 7.5), 10 mM EDTA, 50 mM NaCl, 50 mM NaF, 1%Triton X-100] containing 
10uL/ml Na3VO4 and 15 ul/ml PIC (Protease Inhibitor Cocktail) [500 µM AEBSF, 
hydrochloride, 150 nM aprotinin, bovine lung, crystalline, 1 µM E-64 protease inhibitor, 
0.5 mM EDTA, disodium, and 1 µM leupeptin, hemisulfate]. Whole cell lysates were 
centrifuged. Then, 5X sample buffer [3.8% Tris-base, 50% glycerol, 5% sodium dodecyl 
sulphate (SDS), 5% β-mercaptoethanol, and .0025% bromophenol blue] was added to 
collected supernatant and samples were boiled at 95°C for 5 minutes. Cell lysates were 
loaded on a 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto polyvinylidene difluoride (PVDF) membranes pre-activated by methanol. PVDF 
membranes were blocked with Blotto (2% non-fat dry milk and 0.05% Tween-20 in 
Western Rinse) for 1 hour on a rocker. Following washing with western rinse for 5 minutes, 
membranes were immunoblotted with primary antibodies for 1 hour at room temperature. 
After three washes with western rinse (each time 10 minutes), membranes were incubated 
with secondary antibodies for 1 hour at room temperature. Following three 10 minutes 
washes with western rinse and adding enhanced chemiluminescence (ECL), membranes 
were developed.  
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Immunohistochemistry staining 
 
Human malignant melanoma tissue microarray (ME242c) was purchased from US BioMax 
(Rockville, MD). Rabbit anti–IGPR-1 antibody was used for Immunohistochemical 
staining (1: 700 dilution). IHC Detection Kit Micro-Polymer was purchased from Abcam 
(ab236466). Following standard formalin fixation and paraffin embedding procedure, 
Antigen retrieval was achieved by submerging the slide in 10mM Sodium Citrate and 
0.05% Tween solution (pH 6.0) and heated to 95 degrees Fahrenheit for two 10 minute 
intervals using EZ Retriever System V.2. Antibody detection was performed with 
secondary antibody specific to anti-rabbit primary antibody from Abcam. 
 
 
Immunofluorescence Microscopy 
 
Cover slips were placed in the culture plates, washed with 70% ethanol, and exposed for 
UV light for 30 minutes in a hood. Next, HEK-293 cells expressing pLNCX2-Emerald 
pLNCX2-MIA, pLNCX2-MIA-Emerald were seeded in the plates to 90-100% confluence. 
When cells were completely adherent (after 6 hours), plates were washed once with PBS 
(Phosphate buffered saline) and fixed with freshly prepared 4% paraformaldehyde (PFA) 
for 15 minutes at room temperature. After 3 more washes with PBS, cover slips were 
transferred to labeled glass microscope slides were prepared previously. Finally, slides 
were examined using a fluorescence microscope. 
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Cell Survival and Viability Assays  
Cell survival was assessed by MTT assay according to manufacturer’s recommendation 
(Sigma). Cells were stained with Calcein A (Invitrogen) to measure viability of the cells. 
 
Cell Adhesion and Detachment Assays 
Cells were plated on the gelatin-coated 24-well plates to evaluate cell adhesion. In 
detachment assays cells were cultured in poly-lysine coated dishes (60mm). After 90 
minutes, cells were washed with PBS twice and counted with Open CFU. 
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RESULTS 
 
 
IGPR-1 is downregulated in melanoma cell lines 
 
To address the potential functional role of IGPR-1 in melanoma, we initially examined the 
expression of IGPR-1 in the melanoma cell lines through publicly dataset from The Cancer 
Genome Atlas (TCGA). Our analysis demonstrated that IGPR-1 expression is significantly 
downregulated in all the melanoma cell lines tested. In contrast, expression of IGPR-1 was 
upregulated in most of cancer cell lines, including lung, hematological and colon cancer 
cell lines (Figure 5).  
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Figure 5. IGPR-1 is downregulated in human melanoma cell lines. Compared to other 
cancer cell lines available on TCGA dataset, IGPR-1 expression is downregulated in 
human melanoma cell lines. 
 
Encouraged by our observation, we carried out western blot experiment on several human 
melanoma cell lines and mouse B16F melanoma cell line. Our experiment revealed that 
overall IGPR-1 expression is decreased in all melanoma cell lines. However, as figure 6 
shows different level of IGPR-1 expression have been observed in evaluated cell lines (Fig. 
6).  
 
Figure 6. IGPR-1 expression is downregulated in melanoma cell lines. Cell lysates from 
melanoma cell lines were prepared and subjected to western blot analysis using anti-IGPR-
1 antibody or anti-PLCg1 antibody for protein loading control.  
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IGPR-1 is downregulated in human melanoma tumors 
 
Next, we decided to examine IGPR-1 expression in human melanoma tumors. To this end, 
we performed immunohistochemistry (IHC) staining on a tissue microarray consisting 12 
samples of human melanoma tumors and 12 samples of normal skin and two pathologists 
assessed IGPR-1 staining. IHC analysis demonstrated that IGPR-1 expression is 
significantly reduced in human melanoma tumors compared to normal melanocytes (Fig. 
7). 
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Figure 7. Expression of IGPR-1 is downregulated in human melanoma tumors. (A) 
IGPR-1 expression was scored for staining strength as 0 (no staining), 1 (weak staining), 2 
(moderate staining), or 3 (strong staining). There is significant decrease in IGPR-1 
expression in melanoma compared to adjacent normal skin. (B) A tissue microarray 
consisting 24 samples (12 cases of normal skin and 12 cases of melanoma) for IGPR-1 was 
carried out. Two pathologists assessed IGPR-1 staining. The graph shows that IGPR-1 
expression is downregulated in human melanoma tumors. (Courtesy of Joseph Tashjian 
and Evan G. Sutherland) 
 
 
 
Construction of Human Melanoma Inhibitory Activity (MIA)  
 
There is compelling evidence for involvement of MIA in early development and 
progression of melanoma (A.-K. Bosserhoff, 2005). However, the exact role of MIA in the 
melanoma is not clear. Furthermore, MIA is identified as a IGPR-1 binding protein (Rahimi 
et al., 2012), suggesting a potential role for MIA in IGPR-1 function and vice versa. 
Therefore, we set to produce MIA expression vectors and cell lines to address the role of 
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MIA and IGPR-1 in melanoma. To generate human MIA construct, the full length cDNA 
of MIA was PCR amplified and resultant PCR product was sub-cloned into pLNCX2 vector 
by NOTI and HindIII. In order to investigate effects of MIA expression, we have expressed 
MIA in HEK-293 cells by a retroviral system. Retroviral vector-mediated gene transfer has 
been widely utilized to obtain mass populations of cells expressing similar levels of the 
introduced gene (Ory, Neugeboren, & Mulligan, 1996; Rahimi & Kazlauskas, 1999).  We 
performed all experiments on G418-resistant clones to reduce clonal variations of isolated 
clones. Then, HEK-293 cells expressing pLNCX2-MIA and pLNCX2-Emerald (enhanced 
version of GFP) were lysed and equal amount of proteins of whole cell lysates were 
subjected to western blot analysis using an anti-MIA antibody. 
 
 
Figure 8. Schematic representation of the MIA construct and expression of MIA in 
HEK-293 cells. (A) MIA is constructed by sub-cloning of MIA PCR product into pLNCX2 
vector via NOTI and HindIII restriction sites. (B) An equal number of HEK-293 cells 
expressing MIA and emerald were cultured in 10-cm tissue culture plates, lysed and 
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subjected to western blotting by using an anti-MIA antibody. pLNCX2-Emerald is used as 
a negative control. 
 
 
 
Construction of MIA-Emerald fusion protein 
 
IGPR-1 through its cytoplasmic proline-rich domain interacts with MIA (Rahimi et al., 
2012). However, MIA  is known as a secretory protein (Blesch et al., 1994). This suggests 
that expression of IGPR-1 or lack of its expression in melanoma cells could determine the 
extracellular secretion of MIA. On the other hand, binding MIA to cytoplasmic domain of 
IGPR-1 could generate a distinct signaling pathway that could regulate melanoma cell 
function.    Therefore, first step taken to determine functional relationship between IGPR-
1 and MIA was to investigate cellular distribution of MIA with and without IGPR-1 
expression. To accomplish this, we generated MIA-Emerald fusion protein that allows us 
to localize the presence of MIA with fluorescent microscopy. We introduced Emerald to 
pLNCX2-MIA construct using HindIII and SalI restriction sites and a small linker region 
contains 14 amino acids. Then, to verify the ligation reaction we digest pLNCX2-Emerald 
and pLNCX2-MIA-Emerald with NOTI restriction enzyme and the difference between two 
constructs confirmed efficiency of ligation reaction for pLNCX2-MIA-Emerald.  
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Figure 9. Schematic representation of the construction of MIA-Emerald fusion 
protein. (A) Ligation of Emerald and a linker region into pLNCX2-MIA at HindIII and 
SalI. (B) Analysis of pLNCX2-Emerald and pLNCX2-MIA-Emerald constructs digested 
with NOTI in 0.75 % agarose gel shows the higher molecular weight for bands 
corresponding pLNCX2-MIA-Emerald. 
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In order to further examine the functionality of the MIA-Emerald fusion protein, we 
transfected HEK-293 cells with pLNCX2-MIA, pLNCX2-Emerald and pLNCX2-MIA-
Emerald. After transfection, cells were transferred to 60mm culture plates containing a 
microscope cover slip and subjected to immunofluorescent microscopy. Interestingly, 
images revealed different patterns of Emerald distribution under fluorescent light. Cells 
expressing pLNCX2-Emerald exhibited bright and sharp green light while in pLNCX2-
MIA-Emerald expressing cells green light was faint and diffused in background. This 
contrast in emerald distribution pattern suggested that MIA-Emerald protein is secreted 
from cells similar to MIA. Therefore, it is a unique experimental tool to study effects of 
IGPR-1/MIA interaction.  
 
 
       
A	 B	
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Figure 10. Immunofluorescence microscopy of HEK-293 cells depict different patterns 
of Emerald distribution and suggest MIA-Emerald fusion protein secretion. (A) HEK-
293 cells expressing pLNCX2-Emerald exhibited strong and sharp light distribution. (B) 
HEK-293 cells expressing pLNCX2-MIA-Emerald revealed diffuse and weak light 
distribution. (C) HEK-239 cells expressing pLNCX2-MIA was used as control.  
 
 
 
Suspension Cell Culture and MTT Assay 
 
In order to evaluate the possible effects of MIA, IGPR-1 and MIA/IGPR-1 axis on cell 
adhesion, we culture cells in non-adherent plates. After 24 hours, HEK-293 (as a control) 
did not survive in suspension but other three groups of cells expressing MIA, IGPR-1 and 
MIA/IGPR-1 survived and made clumps of cells in suspension. Interestingly, we observed 
larger clusters of cells with increased survival in IGPR/MIA expressing group. This data 
suggests the probable role of IGPR-1/MIA pathway in tumor metastasis.  
 
 
 
C	
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Figure 11. Suspension cell culture and MTT assay demonstrate that IGPR/MIA 
increases survival. (A) Calcein A is used to confirm cell viability in suspension culture. 
(B) Results of MTT assay indicate higher survival in IGPR/MIA expressing cells. 
 
A	
B	
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Cell Adhesion Experiments  
 
Cells were plated in 24-well cell culture plates coated with gelatin. In MIA expressing 
cells, we observed structures similar to capillary tube formation. However, IGPR/MIA 
expressing cells accumulated in islands. We hypothesized that in the absence of IGPR, 
MIA promotes cell migration. However, expression of IGPR-1 increases cell adhesion and 
prevents cell migration.  
 
Figure 12. Cells were plated on gelatin coated 24-well plates. MIA expressing cells 
migrated (compared to HEK-293 cells) and made capillary tube structures while cells 
expression both MIA and IGPR-1 could not migrate and stayed in groups. 
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Cell Attachment Experiments with Poly-lysine 
In order to further examine the effects of MIA/IGPR-1 pathway on cell attachment to 
extracellular matrix, we cultured cells on poly-lysine coated plates. Counting adherent cells 
in this experiment demonstrated that more cells remained adherent in IGPR/MIA group. 
As seen in Fig13b. MIA expressing cells have clear boundaries, however in cells 
expressing both MIA and IGPR-1, cell boundaries overlapped. Taken together, these 
experiments suggest that IGPR-1 increases the adhesiveness of cells together.  
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Figure 13. Cells were plated on poly-lysine coated plates. (A) Counting adherent via 
Open CFU shows more cells in IGPR/MIA group. (B) IGPR-1 increases cell-cell adhesion 
as the borders are not clear in IGPR/MIA expressing cells. 
 
 
 
 
 
 
 
 
 
 
  
B	
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DISCUSSION 
 
 IGPR-1 is a novel adhesion molecule, which is widely  expressed in endothelial 
and epithelial cells (Rahimi et al., 2012; Wang et al., 2016). Recent research has shown 
several critical functions for IGPR-1.  It is involved in cell-cell adhesion, endothelial barrier 
function, and regulation of angiogenesis (Rahimi et al., 2012; Wang et al., 2016).  
IGPR-1 expression is upregulated in human primary colon cancer and its activity promotes 
tumor growth in cell culture and mouse tumor xenograft. More importantly, inhibition of 
IGPR-1 activity improves sensitivity of colon cancer cells to chemotherapeutic agent, 
doxorubicin (Woolf et al., 2017). A recent study has introduced IGPR-1 as a probable 
immunotherapeutic target in cancer treatment. IGPR-1 binds to HHLA2 which is involved 
in T-cell regulation and predominantly expressed in various human cancers (Janakiram et 
al., 2015).  
Our recent study identified several Src homology domain (SH3) proteins as IGPR-1binding 
partners, including  melanoma inhibitory activity protein (Rahimi et al., 2012), suggesting 
a possible role for IGPR-1 in melanoma. In this study, we investigated IGPR-1 expression 
in melanoma cell lines and human melanoma tumors. Moreover, we generated HEK-293 
cell lines expressing MIA, as a model system to investigate the function of IGPR-1/MIA 
axis in melanoma.  
Our analysis of IGPR-1 expression in melanoma cell lines of publicly available datasets 
via the cancer genome atlas (TCGA), showed that IGPR-1 is downregulated in almost all 
the cell lines tested. However, IGPR-1 was upregulated in majority of other cancer cell 
lines such as hematopoietic, lymphatic, colon and lung. The contrast of IGPR-1 expression 
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between melanoma and other cancer cell lines could imply a unique role of IGPR-1 in 
melanoma.  
In addition, our immunohistochemical analysis on the tissue microarray consisting human 
melanoma tumors, revealed that IGPR-1 expression is significantly decreased in human 
melanoma tumors compared to normal melanocytes.  Taken together, results obtained from 
the TCGA melanoma cell lines and immunohistochemistry staining of human melanoma 
tumors indicated that IGPR-1 is downregulated in human melanoma, suggesting a potential 
role for IGPR-1 in this disease. 
Another important aspect of our study is the demonstration that IGPR-1 is expressed in 
melanoma cell lines at different levels, raising a possibility that IGPR-1 expression status 
could be related to type, grade or other characteristics of cancer cells. In other words, 
although overall IGPR-1 expression is reduced in human melanoma tumors, differences in 
IGPR-1 expression may reflect particular tumor features like angiogenesis, tumor cell 
invasion or migration. In support of this hypothesis, increased capillary tube formation and 
angiogenesis associated with tumor cells have been observed in B16F melanoma cells 
expressing IGPR-1 (Rahimi et al., 2012). Intriguingly, IGPR-1 expression in B16F 
melanoma cells promotes tumor growth, induces senescence-like phenotype and inhibits 
tumor cell migration and invasion (our unpublished data). Results from cell adhesion and 
cell detachment experiments demonstrated that IGPR-1 increases adhesive characteristics 
of cells and prevents MIA-induced migration. Taking into account that  cell invasion, 
migration and metastasis are key determinants of survival and prognosis in melanoma 
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patients (Miller & Mihm Jr, 2006),  these observations further signify the role of IGPR-1 
in melanoma.  
Considering the observed effects of IGPR-1 in melanoma cells, we sought to elucidate the 
functional significance of IGPR-1/MIA interaction. MIA was initially described as a 
soluble protein, which is secreted from melanoma cells and promotes melanoma cell 
invasion.  To date, studies have focused on the function of MIA in the extracellular space 
through its interaction with classical cell adhesion molecules like integrins and fibronectins 
(Riechers & Bosserhoff, 2014). In this study, we proposed a new model for MIA function, 
which is based on its interaction with IGPR-1. In support of possible IGPR-1/MIA axis in 
regulation of melanoma development, our experiments on suspension cell culture and MTT 
assay revealed higher survival rate in IGPR/MIA group compared to both IGPR-1 and MIA 
groups. This observation is congruent with our hypothesis that MIA binding to IGPR-1 is 
involved in regulation of melanoma metastasis. IGPR-1/MIA pathway activation prevents 
MIA from its interactions with extracellular matrix components and pegs MIA as a 
signaling protein in cytoplasm. Therefore, MIA could regulated IGPR-1-dependnet 
functions in melanoma cells such as promotion of tumor growth, prevention of cell 
migration and induction of senescence-like phenotype. Figure 11 summarize the proposed 
function of MIA in IGPR-1 signaling.  
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Figure 14. The proposed function of MIA in the presence of IGPR-1. MIA binding to 
IGPR-1 decreases MIA activity in extracellular space. IGPR-1/MIA interaction could 
promote tumor growth, prevent cell migration and induce cell senescence. 
 
Melanoma is the deadliest form of skin cancer with increasing both incident and mortality 
rate. Current therapeutic approaches are concentrated on early detection and surgical 
resection of primary localized tumors. However, research has shown that 30 percent of 
melanoma patients develop metastasis,  which is the main cause of melanoma related 
deaths (Sandru et al., 2014). Some studies have suggested MIA as a therapeutic target or 
prognostic factor (Domingues, Lopes, Soares, & Pópulo, 2018). However, further studies 
on MIA and the associated mechanisms could provide new insights into the involvement 
of MIA in melanoma and its possible function in IGPR-1 signaling pathway.   
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